What Is The Current and Historic Market Size Analysis Of The Advanced Renal Cell Carcinoma Treatment Market?
The advanced renal cell carcinoma treatment market has seen considerable growth due to a variety of factors.
• In recent times, the market size for advanced renal cell carcinoma treatment has experienced robust growth. It is projected to expand from $8.10 billion in 2024 to $8.75 billion in 2025, with a compound annual growth rate (CAGR) of 8.1%.
Factors contributing to the growth during the historical period include a rising percentage of elderly people, an escalated smoking ratio, a surge in hypertension incidents, enhanced healthcare spending, and an increase in renal cancer cases.
What are the Market Size and Expected Growth Rates for the Advanced Renal Cell Carcinoma Treatment Template Market?
The advanced renal cell carcinoma treatment market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for the advanced renal cell carcinoma treatment market, as its size is forecasted to experience significant growth in the upcoming years. By 2029, the market is projected to reach a value of $11.77 billion, growing at a compound annual growth rate (CAGR) of 7.7%.
Factors contributing to the prospective growth in this period include an increase in cases of genetic disorders, a surge in the prevalence of chronic hypertension, the acceptance of tyrosine kinase inhibitors, heightened awareness regarding kidney cancer, and increased investment in research and development. The forecast period is also expected to see notable trends including breakthroughs in diagnostic technology, advancements in targeted treatments, the emergence of oral therapies, progress in liquid biopsy methods, and the integration of artificial intelligence in drug discovery.
Which Key Drivers Are Propelling The Advanced Renal Cell Carcinoma Treatment Market's Growth?
The surge in genetic conditions is predicted to drive the expansion of the advanced renal cell carcinoma (RCC) treatment market. Genetic conditions involve diseases or disorders triggered by DNA anomalies in a person, which can be hereditary or can occur from mutations throughout a person's life. The rise in these conditions can be linked to factors like the progression in diagnostic technologies, increased awareness and reporting, alongside lifestyle modifications and environmental impacts that may interact with genetic predispositions. Advanced RCC treatments play a role in managing these conditions by targeting particular molecular pathways, offering personalized treatments that tackle the genetic contributors to tumor growth and advancement. For example, in June 2023, Gene People, a recognized charity in the UK, calculated that 1 in 25 children is impacted by genetic conditions, and beyond 2.4 million people in the UK live with a genetic disorder. Furthermore, approximately 30,000 babies and children are identified with genetic conditions annually in the UK. Consequently, the rise in genetic conditions is propelling the growth of the advanced renal cell carcinoma (RCC) treatment market.
What Are The Key Segments Within The Global Advanced Renal Cell Carcinoma Treatment Market?
The advanced renal cell carcinoma treatment market covered in this report is segmented –
1) By Treatment: Biologics, Radiation Therapy, Chemotherapy, Hormone, Vaccine Therapy, Other Treatments
2) By Route Of Administration: Parental, Oral, Other Route Of Administrations
3) By End User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Biologics: Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cytokine Therapy, Targeted Small Molecule Inhibitors
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Body Radiation Therapy (SBRT), Proton Beam Therapy
3) By Chemotherapy: Platinum-Based Chemotherapy, Antimetabolites, Alkylating Agents
4) By Hormone Therapy: Androgen Deprivation Therapy (ADT), Estrogen Receptor Modulators
5) By Vaccine Therapy: Peptide-Based Cancer Vaccines, Dendritic Cell Vaccines, DNA-Based Cancer Vaccines
6) By Other Treatments: Cryoablation, Radiofrequency Ablation (RFA), Combination Therapy
Pre-Book The Advanced Renal Cell Carcinoma Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Advanced Renal Cell Carcinoma Treatment Market?
Key players in the market for advanced renal cell carcinoma (RCC) treatment are honing their focus on producing novel medical products such as hypoxia-inducible factor-2 alpha (HIF-2a) inhibitors. These inhibitors are envisaged to increase the effectiveness of treatments and yield better results for patients. HIF-2a inhibitors are specially crafted medicines that inhibit the functionality of the HIF-2a protein, instrumental for managing low oxygen level responses in the body. In a significant development in December 2023, Merck & Co. Inc., a healthcare corporation based in the United States, was granted approval by the U.S Food and Drug Administration (FDA) for WELIREG (belzutifan), a HIF-2a inhibitor that's administered orally. Notably designed for patients who have prior exposure to treatments with PD-1 or PD-L1 inhibitors and VEGF-TKI therapies, the approval of WELIREG signifies a promising new direction forward for a group that currently has scarce treatment alternatives. It presents potential for not just improved results, but an enhanced handling of advanced RCC.
Who Are the Key Players In The Advanced Renal Cell Carcinoma Treatment Market?
Major companies operating in the advanced renal cell carcinoma treatment market are:
• Pfizer Inc.
• Merck & Co. Inc.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Ipsen SA
• Exelixis Inc.
• BeiGene Ltd.
• Bavarian Nordic A/S
• Telix Pharmaceuticals Limited
• CRISPR Therapeutics AG
• Beijing Scitech-Mq Pharmaceuticals Limited
• HUTCHMED (China) Limited
• Arcus Biosciences Inc.
• NGM Biopharmaceuticals Inc.
• Mirati Therapeutics Inc.
What Are The Regional Insights Into The Advanced Renal Cell Carcinoma Treatment Market?
North America was the largest region in the advanced renal cell carcinoma treatment market in 2024. The regions covered in the advanced renal cell carcinoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
